Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …

Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and
account for nearly all cancer-related deaths. Both metastasis and therapy resistance are …

The epithelial–mesenchymal transition (EMT) and cancer stem cell (CSC) formation are two
paramount processes driving tumor progression, therapy resistance, and cancer metastasis …

Our understanding of epithelial-to-mesenchymal transition (EMT) has slowly evolved from a
simple two state, binary model to a multi-step, dynamic continuum of epithelial-to …

Over the past decade, cancer diagnosis has expanded to include liquid biopsies in addition
to tissue biopsies. Liquid biopsies can result in earlier and more accurate diagnosis and …

Genetic and phenotypic heterogeneity contribute to the generation of diverse tumor cell
populations, thus enhancing cancer aggressiveness and therapy resistance. Compared to …

Tumor cells demonstrate substantial plasticity in their genotypic and phenotypic
characteristics. Epithelial-mesenchymal plasticity (EMP) can be characterized into dynamic …

Metastasis is the cause of over 90% of cancer-related deaths. Cancer cells undergoing
metastasis can switch dynamically between different phenotypes, enabling them to adapt to …

The nonsteroidal anti‐inflammatory agent aspirin is widely used for preventing and treating
cardiovascular and cerebrovascular diseases. In addition, epidemiologic evidences reveal …

In the process of cancer EMT, some subgroups of cancer cells simultaneously exhibit both
mesenchymal and epithelial characteristics, a phenomenon termed partial EMT (pEMT) …